<DOC>
	<DOCNO>NCT00643097</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill tumor cell . Colony-stimulating factor , GM-CSF , increase number white blood cell platelets find bone marrow peripheral blood . Giving vaccine therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well vaccine therapy work treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess humoral cellular immune response adjuvant PEP-3-KLH conjugate vaccine patient newly diagnose glioblastoma multiforme ( GBM ) . - To assess clinical efficacy PEP-3-KLH conjugate vaccine , term progression-free survival , patient newly diagnose GBM . Secondary - To determine whether patient GBM , know least mildly immunosuppressed , respond standard proven vaccine strategy . - To assess potential toxicity PEP-3-KLH conjugate vaccine patient newly diagnose GBM . OUTLINE : This multicenter study . Patients stratify accord participate center . At time study initiate , standard care temozolomide establish , therefore , Arm I ( ACTIVATE ) give without monthly cycle temozolomide . At point interim analysis , monthly cycle temozolomide become standard care . Arm II give standard care 5-day cycle monthly temozolomide time , dose-intensified temozolomide trial compare 5-day temozolomide . Therefore , Arm III initiate determine immunologic effect 21-day monthly cycle temozolomide vaccine . - Arm I ( ACTIVATE ) : Patients receive PEP-3-KLH conjugate vaccine sargramostim ( GM-CSF ) intradermally day 1 , 15 , 29 monthly absence disease progression unacceptable toxicity . - Arm II ( ACT II Standard ( STD ) ) : Patients first receive 3 initial vaccination epidermal growth factor receptor variant III ( EGRRvIII ) - specific peptide ( PEP-3 ) keyhole limpet hemocyanin ( KLH ) conjugate vaccine sargramostim ( GM-CSF ) biweekly start within 6 week complete radiation . Additional vaccination give clinical radiographic evidence progression death . Patients subsequently receive temozolomide target dose 200 mg/m2 first 5 day 28 day cycle . - Arm III ( ACT II Dose-intensified ( DI ) ) : Patients first receive 3 initial vaccination epidermal growth factor receptor variant III ( EGRRvIII ) - specific peptide ( PEP-3 ) keyhole limpet hemocyanin ( KLH ) conjugate vaccine sargramostim ( GM-CSF ) biweekly start within 6 week complete radiation . Additional vaccination give clinical radiographic evidence progression death . Patients subsequently receive temozolomide target dose 100 mg/m2 first 21 day 28 day cycle . - Patients undergo delayed-type hypersensitivity ( DTH ) skin testing* baseline , third vaccination , monthly thereafter . Patients also undergo leukapheresis obtain sufficient peripheral blood lymphocytes immunologic monitoring baseline , third vaccination , , applicable , time positive DTH response , disease progression , sixth course post-radiotherapy temozolomide . Methods use immunologic monitoring include Enzyme-linked Immunospot ( ELISPOT ) assay , cytotoxicity assay , fluorescence activate cell sorting ( FACS ) , ELISA . NOTE : *Patients positive DTH skin testing , also undergo skin punch biopsy . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Histologically confirm newly diagnose glioblastoma multiforme Has undergone prior gross total resection ( GTR ) follow conformal radiotherapy* without concurrent chemotherapy GTR define ≥ 95 % volumetric resection contrastenhancing component preoperative MRI Residual radiographic contrast enhancement postresection CT scan MRI must ≤ 1 cm maximal diameter two perpendicular axial plane No evidence disease progression completion radiotherapy* NOTE : *Patients may enroll part 2 study within 2 week surgery ; patient receive radiotherapy concurrent chemotherapy study EGFRvIIIpositive tumor immunohistochemistry , polymerase chain reaction , related molecular technique Karnofsky performance status 80100 % Curran group status IIV Signed informed consent form Absolute Neutrophil Count ( ANC ) &lt; 1,000/mm³ Platelet count &lt; 50,000/mm³ Prothrombin Time/Partial Thromboplastin Time ( PT/PTT ) &gt; 1.5 time normal Positive hepatitis B ( HB ) surface antigen ( HbsAg ) , antibody hepatitis B surface antigen ( antiHBs ) , antibody hepatitis B core antigen ( antiHBc ) Pregnant nursing Positive pregnancy test Active infection require treatment Unexplained febrile illness ( T max &gt; 101.5 F ) Inflammatory bowel disease , lupus erythematosus , rheumatoid arthritis , autoimmune disease Known immunosuppressive disease Known HIV infection Diffuse leptomeningeal disease Unstable severe concurrent medical condition , severe heart lung disease active hepatitis Demonstrated allergy temozolomide inability tolerate temozolomide reason lymphopenia Concurrent corticosteroid ( except nasal inhaled steroid ) dose physiologic level ( &gt; 2 mg dexamethasone/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>